Compared with a ‘one-size-fits-all’ approach, biomarker directed therapy has revolutionised standards of care for many cancer types, such as HER2-directed therapy in breast cancer and small molecule inhibitors in non-small cell lung cancer [30–33]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.